Abstract
Background: Statins are the first-line agents used to treat patients with high serum low-density lipoprotein cholesterol levels, thus reducing the risk of death from arterial sclerotic cardiovascular disease; however, little is known about the effects of non-statin pharmacological interventions on mortality as well as about the potential protective effects of statin use against cancer death. This work aimed to compare all-cause and cancer mortality among patients with hyperlipidaemia who did and did not receive statin treatment. Methods: Between 2003 and 2007 fiscal years, we recruited Japanese patients diagnosed with hyperlipidaemia from 66 hospitals. Patients in our cohort were followed up for a maximum of 12 years to observe the causes of death. KaplaneMeier estimates from the baseline were used to compare the mortality of patients based on the administered medicine. All-cause mortality were compared among patients with/without administration of statins and other agents; any-organ and colorectal cancer mortality were compared between patients with/without administration of statins. Results: Our cohort included 41,930 patients with mean ages of 64e66 years and mean body mass indices of 24e25 kg/m2. Patients who received statin monotherapy and were treated with lifestyle modification exhibited nearly identical survival curves, whereas statin use represented a non-significant but potentially protective effect against colorectal cancer-related mortality. The lowest mortality in this cohort was associated with resin monotherapy. Conclusions: Mortality rate has been similar for patients treated with statin monotherapy and lifestyle modification. Statinmonotherapycouldpotentially reduceany-organ- andcolorectal cancer-relatedmortality.
| Original language | English |
|---|---|
| Pages (from-to) | S84-S91 |
| Journal | Journal of epidemiology |
| Volume | 27 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 01-01-2017 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Epidemiology
Cite this
}
Statin use and all-cause and cancer mortality : BioBank Japan cohort. / BioBank Japan Cooperative Hospital Group.
In: Journal of epidemiology, Vol. 27, No. 3, 01.01.2017, p. S84-S91.Research output: Contribution to journal › Article
TY - JOUR
T1 - Statin use and all-cause and cancer mortality
T2 - BioBank Japan cohort
AU - BioBank Japan Cooperative Hospital Group
AU - Yokomichi, Hiroshi
AU - Nagai, Akiko
AU - Hirata, Makoto
AU - Tamakoshi, Akiko
AU - Kiyohara, Yutaka
AU - Kamatani, Yoichiro
AU - Muto, Kaori
AU - Ninomiya, Toshiharu
AU - Matsuda, Koichi
AU - Kubo, Michiaki
AU - Nakamura, Yusuke
AU - Yamagata, Zentaro
AU - Misumi, Kazuo
AU - Kubo, Michiaki
AU - Matsubayashi, Sunao
AU - Matsuura, Kei
AU - Minami, Shiro
AU - Sugihara, Hitoshi
AU - Emoto, Naoya
AU - Ohmura, Hirotoshi
AU - Inui, Akihiro
AU - Ogasawara, Michihiro
AU - Asai, Satoshi
AU - Moriyama, Mitsuhiko
AU - Takahashi, Yasuo
AU - Fujioka, Tomoaki
AU - Obara, Wataru
AU - Mori, Seijiro
AU - Ito, Hideki
AU - Nagayama, Satoshi
AU - Miki, Yoshio
AU - Masumoto, Akihide
AU - Yamada, Akira
AU - Nishizawa, Yasuko
AU - Kodama, Ken
AU - Ugi, Satoshi
AU - Maegawa, Hiroshi
AU - Koretsune, Yukihiro
AU - Kusuoka, Hideo
AU - Ueyama, Masako
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Background: Statins are the first-line agents used to treat patients with high serum low-density lipoprotein cholesterol levels, thus reducing the risk of death from arterial sclerotic cardiovascular disease; however, little is known about the effects of non-statin pharmacological interventions on mortality as well as about the potential protective effects of statin use against cancer death. This work aimed to compare all-cause and cancer mortality among patients with hyperlipidaemia who did and did not receive statin treatment. Methods: Between 2003 and 2007 fiscal years, we recruited Japanese patients diagnosed with hyperlipidaemia from 66 hospitals. Patients in our cohort were followed up for a maximum of 12 years to observe the causes of death. KaplaneMeier estimates from the baseline were used to compare the mortality of patients based on the administered medicine. All-cause mortality were compared among patients with/without administration of statins and other agents; any-organ and colorectal cancer mortality were compared between patients with/without administration of statins. Results: Our cohort included 41,930 patients with mean ages of 64e66 years and mean body mass indices of 24e25 kg/m2. Patients who received statin monotherapy and were treated with lifestyle modification exhibited nearly identical survival curves, whereas statin use represented a non-significant but potentially protective effect against colorectal cancer-related mortality. The lowest mortality in this cohort was associated with resin monotherapy. Conclusions: Mortality rate has been similar for patients treated with statin monotherapy and lifestyle modification. Statinmonotherapycouldpotentially reduceany-organ- andcolorectal cancer-relatedmortality.
AB - Background: Statins are the first-line agents used to treat patients with high serum low-density lipoprotein cholesterol levels, thus reducing the risk of death from arterial sclerotic cardiovascular disease; however, little is known about the effects of non-statin pharmacological interventions on mortality as well as about the potential protective effects of statin use against cancer death. This work aimed to compare all-cause and cancer mortality among patients with hyperlipidaemia who did and did not receive statin treatment. Methods: Between 2003 and 2007 fiscal years, we recruited Japanese patients diagnosed with hyperlipidaemia from 66 hospitals. Patients in our cohort were followed up for a maximum of 12 years to observe the causes of death. KaplaneMeier estimates from the baseline were used to compare the mortality of patients based on the administered medicine. All-cause mortality were compared among patients with/without administration of statins and other agents; any-organ and colorectal cancer mortality were compared between patients with/without administration of statins. Results: Our cohort included 41,930 patients with mean ages of 64e66 years and mean body mass indices of 24e25 kg/m2. Patients who received statin monotherapy and were treated with lifestyle modification exhibited nearly identical survival curves, whereas statin use represented a non-significant but potentially protective effect against colorectal cancer-related mortality. The lowest mortality in this cohort was associated with resin monotherapy. Conclusions: Mortality rate has been similar for patients treated with statin monotherapy and lifestyle modification. Statinmonotherapycouldpotentially reduceany-organ- andcolorectal cancer-relatedmortality.
UR - http://www.scopus.com/inward/record.url?scp=85016403176&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016403176&partnerID=8YFLogxK
U2 - 10.1016/j.je.2016.12.011
DO - 10.1016/j.je.2016.12.011
M3 - Article
VL - 27
SP - S84-S91
JO - Journal of Epidemiology
JF - Journal of Epidemiology
SN - 0917-5040
IS - 3
ER -